These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343 [TBL] [Abstract][Full Text] [Related]
7. Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique. Santra M; Shaughnessy JD; Bellamy WT Biotech Histochem; 2011 Apr; 86(2):119-23. PubMed ID: 20438295 [TBL] [Abstract][Full Text] [Related]
8. Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma. Atalay F; Ateşoğlu EB; Yıldız S; Firatlı-Tuglular T; Karakuş S; Bayık M Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):164-70. PubMed ID: 25445472 [TBL] [Abstract][Full Text] [Related]
9. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172 [TBL] [Abstract][Full Text] [Related]
10. [Multiple Myeloma]. Yano H; Iida S Gan To Kagaku Ryoho; 2014 May; 41(5):580-6. PubMed ID: 24956631 [No Abstract] [Full Text] [Related]
11. Plasma cell myeloma with histiocyte-like morphology. Zhu J; Pan B; Yao J; Guo W Int J Hematol; 2017 Sep; 106(3):307-309. PubMed ID: 28555415 [No Abstract] [Full Text] [Related]
12. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Chen MH; Qi C; Reece D; Chang H Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644 [TBL] [Abstract][Full Text] [Related]
13. Plasma cell myeloma mimicking classical Hodgkin lymphoma in the bone marrow. Karner KH; Inamdar KV Int J Hematol; 2018 Feb; 107(2):127-128. PubMed ID: 29027630 [No Abstract] [Full Text] [Related]
14. Significance of bone marrow biopsy in the multiple myeloma. Bartl R; Burkhardt R; Gierster P; Sandel P; Fateh-Moghadam A Bibl Haematol; 1978; 45():81-6. PubMed ID: 747638 [No Abstract] [Full Text] [Related]
15. Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. de Waal EG; Leene M; Veeger N; Vos HJ; Ong F; Smit WG; Hovenga S; Hoogendoorn M; Hogenes M; Beijert M; Diepstra A; Vellenga E Br J Haematol; 2016 Nov; 175(4):661-667. PubMed ID: 27605358 [TBL] [Abstract][Full Text] [Related]
16. Relapse of multiple myeloma: diagnosis by clot section alone with negative bone marrow aspirate and trephine biopsy. Kakkar N; Das S Indian J Pathol Microbiol; 2009; 52(2):290-1. PubMed ID: 19332952 [No Abstract] [Full Text] [Related]
17. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177 [TBL] [Abstract][Full Text] [Related]
18. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma. Fan L; Hong J; Huang H; Fu D; Wu S; Wang Q; Ye Y; Liu Y Med Sci Monit; 2017 May; 23():2636-2643. PubMed ID: 28557972 [TBL] [Abstract][Full Text] [Related]
19. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies. Chai KY; Boyke Berahmana AA; Morison IM Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997 [No Abstract] [Full Text] [Related]
20. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Vrábel D; Pour L; Ševčíková S Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]